Dai Chihara

4.1k total citations
128 papers, 2.1k citations indexed

About

Dai Chihara is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Dai Chihara has authored 128 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pathology and Forensic Medicine, 56 papers in Oncology and 39 papers in Genetics. Recurrent topics in Dai Chihara's work include Lymphoma Diagnosis and Treatment (88 papers), Viral-associated cancers and disorders (33 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Dai Chihara is often cited by papers focused on Lymphoma Diagnosis and Treatment (88 papers), Viral-associated cancers and disorders (33 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Dai Chihara collaborates with scholars based in United States, Japan and Australia. Dai Chihara's co-authors include Hidemi Ito, Keitaro Matsuo, Tomohiro Matsuda, Yasuhiro Oki, Loretta J. Nastoupil, Akiko Shibata, Tomotaka Sobue, Nathan Fowler, Shigeo Nakamura and Lindsay M. Morton and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Dai Chihara

120 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dai Chihara United States 25 1.2k 932 662 477 359 128 2.1k
Emmanuel Bachy France 26 1.2k 1.0× 1.3k 1.4× 450 0.7× 379 0.8× 235 0.7× 185 2.3k
Wilhelm Woessmann Germany 26 1.2k 1.0× 740 0.8× 314 0.5× 359 0.8× 417 1.2× 65 2.0k
David Simpson New Zealand 20 1.3k 1.1× 830 0.9× 1.1k 1.7× 329 0.7× 438 1.2× 77 2.2k
Lydia Scarfò Italy 27 940 0.8× 645 0.7× 1.2k 1.8× 833 1.7× 279 0.8× 111 2.3k
E. Condé Spain 21 1.1k 1.0× 943 1.0× 452 0.7× 314 0.7× 284 0.8× 43 1.7k
Kirit M. Ardeshna United Kingdom 27 2.1k 1.8× 1.9k 2.0× 758 1.1× 688 1.4× 137 0.4× 120 3.3k
Dennis P. O’Malley United States 25 654 0.5× 552 0.6× 467 0.7× 242 0.5× 318 0.9× 92 1.9k
Kosei Matsue Japan 29 1.1k 1.0× 1.1k 1.1× 736 1.1× 467 1.0× 1.3k 3.7× 213 3.2k
Carmen Canals Spain 24 1.2k 1.0× 1.1k 1.2× 548 0.8× 579 1.2× 1.1k 3.0× 51 2.3k
William Townsend United Kingdom 22 897 0.8× 877 0.9× 365 0.6× 375 0.8× 96 0.3× 68 1.8k

Countries citing papers authored by Dai Chihara

Since Specialization
Citations

This map shows the geographic impact of Dai Chihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dai Chihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dai Chihara more than expected).

Fields of papers citing papers by Dai Chihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dai Chihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dai Chihara. The network helps show where Dai Chihara may publish in the future.

Co-authorship network of co-authors of Dai Chihara

This figure shows the co-authorship network connecting the top 25 collaborators of Dai Chihara. A scholar is included among the top collaborators of Dai Chihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dai Chihara. Dai Chihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chihara, Dai, et al.. (2025). Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis. PubMed. 2(2). 100080–100080. 1 indexed citations
2.
Strati, Paolo, Lei Feng, Jason R. Westin, et al.. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nature Communications. 16(1). 7300–7300.
3.
Li, Meng, Rahul K. Shah, Ruitao Lin, et al.. (2025). Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019. Blood Advances. 10(5). 1713–1721.
4.
Strati, Paolo, Dai Chihara, Jason R. Westin, et al.. (2025). A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 31(19). 4079–4088.
5.
Li, Meng, et al.. (2024). Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2023. Blood. 144(Supplement 1). 7597–7597.
6.
Chihara, Dai, Michael J. Kane, Christopher R. Flowers, & Brian P. Hobbs. (2024). Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma. Blood. 144(Supplement 1). 4462–4462. 1 indexed citations
7.
Westin, Jason R., Loretta J. Nastoupil, Ranjit Nair, et al.. (2024). Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7044–7044. 4 indexed citations
8.
Link, Brian K., Matthew J. Maurer, Melissa C. Larson, et al.. (2024). Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Advances. 8(23). 5939–5948. 2 indexed citations
9.
Wu, Susan, Penny Fang, Kelsey L. Corrigan, et al.. (2024). Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung. Advances in Radiation Oncology. 9(12). 101648–101648. 1 indexed citations
10.
Corrigan, Kelsey L., Benjamin R. Schrank, Lewis Nasr, et al.. (2024). Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Frontiers in Oncology. 14. 1447020–1447020.
11.
Olszewski, Adam J., Narendranath Epperla, Dai Chihara, & Thomas Ollila. (2023). IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSIS. Hematological Oncology. 41(S2). 107–108. 1 indexed citations
12.
Alderuccio, Juan Pablo, Isildinha M. Reis, Jean L. Koff, et al.. (2023). Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood. 141(15). 1888–1893. 6 indexed citations
13.
Chihara, Dai, Miloš D. Miljković, Swaminathan P. Iyer, & Francisco Vega. (2021). Targeted based therapy in nodal T-cell lymphomas. Leukemia. 35(4). 956–967. 5 indexed citations
14.
Kondo, Eisei, Takashi Ikeda, Koji Izutsu, et al.. (2019). High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biology of Blood and Marrow Transplantation. 25(5). 899–905. 14 indexed citations
15.
Chihara, Dai, Yasuhiro Oki, Michelle A. Fanale, et al.. (2019). Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Annals of Hematology. 98(5). 1169–1176. 11 indexed citations
16.
Chihara, Dai, Nathan Fowler, Yasuhiro Oki, et al.. (2017). Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. Blood. 130. 4137–4137. 1 indexed citations
17.
Cheah, Chan Y., Dai Chihara, S. Horowitz, et al.. (2016). Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27(7). 1317–1323. 21 indexed citations
18.
Cheah, Chan Y., Dai Chihara, Jorge Romaguera, et al.. (2015). Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Annals of Oncology. 26(6). 1175–1179. 122 indexed citations
19.
Chihara, Dai & Yasuhiro Oki. (2014). Brentuximab vedotin for treatment of systemic T-cell lymphoma. Expert Opinion on Biological Therapy. 14(10). 1519–1526. 2 indexed citations
20.
Chihara, Dai, Yasuhiro Oki, Hiroshi Onoda, et al.. (2011). High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. International Journal of Hematology. 93(4). 502–508. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emmanuel Bachy Breakdown of academic impact, for papers by Wilhelm Woessmann Breakdown of academic impact, for papers by David Simpson Breakdown of academic impact, for papers by Lydia Scarfò Breakdown of academic impact, for papers by E. Condé Breakdown of academic impact, for papers by Kirit M. Ardeshna Breakdown of academic impact, for papers by Dennis P. O’Malley Breakdown of academic impact, for papers by Kosei Matsue Breakdown of academic impact, for papers by Carmen Canals Breakdown of academic impact, for papers by William Townsend
Rankless by CCL
2026